Modulation of the Generation of Dopaminergic Neurons from Human Neural Stem Cells by Bcl-X L . Mechanisms of Action.

Vitamins and Hormones

Volumn 87, Issue , 2011, Pages 175-205

  Martínez Serrano, Alberto ^a   Castillo, Claudia G ^b   Courtois, Elise T ^c   García García, Elisa ^a   Liste, Isabel ^a,d  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cell death and survival; Cell fate decisions; Genetic manipulation; Human dopaminergic neurons; Human neural precursors; Ventral mesencephalon

Indexed keywords

EID: 84857127646     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386015-6.00029-9     Document Type: Chapter

References (140)

1. Abeilovich A., Hammond R. Midbrain dopamine neuron differentiation: Factors and facts. Dev. Biol. 2007, 304:447-454.
2. Akchiche N., Bossenmeyer-Pourie C., Pourie G., Koziel V., Nedelec E., Gueant J.L., Daval J.L. Differentiation and neural integration of hippocampal neuronal progenitors: Signaling pathways sequentially involved. Hippocampus 2010, 20:949-961.
3. Alavian K.N., Scholz C., Simon H.H. Transcriptional regulation of mesencephalic dopaminergic neurons: The full circle of life and death. Mov. Disord. 2008, 23:319-328.
4. Andersson E., Jensen J.B., Parmar M., Guillemot F., Bjorklund A. Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2. Development 2006, 133:507-516.
5. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., Perlmann T., Ericson J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006, 124:393-405.
6. Andersson E.K., Irvin D.K., Ahlsio J., Parmar M. Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells. Exp. Cell Res. 2007, 313:1172-1180.
7. Ang S.L. Transcriptional control of midbrain dopaminergic neuron development. Development 2006, 133:3499-3506.
8. Aranha M.M., Sola S., Low W.C., Steer C.J., Rodrigues C.M. Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J. Cell. Biochem. 2009, 107:748-758.
9. Arbour N., Vanderluit J.L., Le Grand J.N., Jahani-Asl A., Ruzhynsky V.A., Cheung E.C., Kelly M.A., MacKenzie A.E., Park D.S., Opferman J.T., Slack R.S. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 2008, 28:6068-6078.
10. Arenas E. Towards stem cell replacement therapies for Parkinsońs disease. Biochem. Biophys. Res. Commun. 2010, 21:152-156.
11. Aubert J., Stavridis M.P., Tweedie S., O'Reilly M., Vierlinger K., Li M., Ghazal P., Pratt T., Mason J.O., Roy D., Smith A. Screening for mammalian neural genes via fluorescence-activated cell sorter purification of neural precursors from Sox1-gfp knock-in mice. Proc. Natl. Acad. Sci. USA 2003, 100:11836-11841.
12. Benn S.C., Woolf C.J. Adult neuron survival strategies-Slamming on the brakes. Nat. Rev. Neurosci. 2004, 5:686-700.
13. Bjorklund A., Dunnet S.B. Dopamine neuron systems in the brain: An update. Trends Neurosci. 2007, 30:194-202.
14. Bonilla S., Hall A.C., Pinto L., Attardo A., Götz M., Huttner W.B., Arenas E. Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors. Glia 2008, 56:809-820.
15. Brundin P., Barker R.A., Parmar M. Neural grafting in Parkinson's disease: Problems and possibilities. Prog. Brain Res. 2010, 184:265-294.
16. Cai J., Donaldson A., Yang M., German M.S., Enikolopov G., Iacovitti L. The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells 2009, 27:220-229.
17. Calegari F., Huttner W.B. An inhibition of cyclin-dependent kinases that lengthens, but does not arrest, neuroepithelial cell cycle induces premature neurogenesis. J. Cell Sci. 2003, 116:4947-4955.
18. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res. 2008, 17:465-478.
19. Castelo-Branco G., Arenas E. Function of Wnts in dopaminergic neuron development. Neurodegener Dis 2006, 3:5-11.
20. Castelo-Branco G., Wagner J., Rodriguez F.J., Kele J., Sousa K., Rawal N., Pasolli H.A., Fuchs E., Kitajewski J., Arenas E. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and wnt-5a. Proc. Natl. Acad. Sci. USA 2003, 100:12747-12752.
21. Castelo-Branco G., Rawal N., Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J. Cell Sci. 2004, 117:5731-5737.
22. Chambers S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signalling. Nat. Biotechnol. 2009, 27:275-280.
23. Chang M.Y., Sun W., Ochiai W., Nakashima K., Kim S.Y., Park C.H., Kang J.S., Shim J.W., Jo A.Y., Kang C.S., Lee Y.S., Kim J.S., et al. Bcl-XL/Bax proteins direct the fate of embryonic cortical precursor cells. Mol. Cell. Biol. 2007, 27:4293-4305.
24. Cho M.S., et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 2008, 105:3392-3397.
25. Chung S., Shin B.S., Hwang M., Lardaro T., Kang U.J., Isacson O., Kim K.S. Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells 2006, 24:1583-1593.
26. Cory S., Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
27. Courtois E.T., Castillo C.G., Seiz E.G., Ramos M., Bueno C., Liste I., Martinez-Serrano A. In vitro and in vivo enhanced generation of human A9 dopamine neurons from neural stem cells by Bcl-XL. J. Biol. Chem. 2010, 285:9881-9897.
28. Dehay C., Kennedy H. Cell-cycle control and cortical development. Nat. Rev. Neurosci. 2007, 8:438-450.
29. Doe C.Q. Neural stem cells: Balancing self-renewal with differentiation. Development 2008, 135:1575-1587.
30. Donato R., Miljan E.A., Hines S.J., Aouabdi S., Pollock K., Patel S., Edwards F.A., Sinden J.D. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007, 8:36.
31. Dunnett S.B., Björklund A., Lindvall O. Cell therapy in Parkinson's disease-Stop or go?. Nat. Rev. Neurosci. 2001, 2:365-369.
32. Farkas L.M., Haffner C., Giger T., Khaitovich P., Nowick K., Birchmeier C., Paabo S., Huttner W.B. Insulinoma-associated 1 has a panneurogenic role and promotes the generation and expansion of basal progenitors in the developing mouse neocortex. Neuron 2008, 60:40-55.
33. Ferri A.L.M., Lin W., Mavromatakis Y.E., Wang J.C., Sasaki H., Whitsett J.A., Ang S.L. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development 2007, 134:2761-2769.
34. Friling S., Andersson E., Thompson L.H., Jönsson M.E., Hebsgaard J.B., Nanou E., Alekseenko Z., Marklund U., Kjellander S., Volakakis N., Hovatta O., El Manira A., et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc. Natl. Acad. Sci. USA 2009, 106(18):7613-7618.
35. Gale E., Li M. Midbrain dopaminergic neuron fate specification: Of mice and embryonic stem cells. Mol. Brain 2008, 1:8.
36. Garrido C., Kroemer G. Life's smile, death's grin: Vital functions of apoptosis-executing proteins. Curr. Opin. Cell Biol. 2004, 16:639-646.
37. Gonzalez-Garcia M., Perez-Ballestero R., Ding L., Duan L., Boise L.H., Thompson C.B., Nunez G. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994, 120:3033-3042.
38. Grealish S., Jonsson M.E., Li M., Kirik D., Bjorklund A., Thompson L.H. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133:482-495.
39. Gu Y., Siefring J.E., Wang L., Chae H.D., Bailey J.R., Zheng Y. Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation. Oncogene 2006, 25:3963-3972.
40. Guillemot F. Cell fate specification in the mammalian telencephalon. Prog. Neurobiol. 2007, 83:37-52.
41. Hagell P., Piccin P., Björklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
42. Hagn F., Klein C., Demmer O., Marchenko N., Vaseva A., Moll U.M., Kessler H. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J. Biol. Chem. 2010, 285:3439-3450.
43. Hall V., Li J.Y., Brundin P. Restorative cell therapy for Parkinson's disease: A quest for the perfect cell. Semin. Cell Dev. Biol. 2007, 18:859-869.
44. Hargus G., et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc. Natl. Acad. Sci. USA 2010, 107:15921-15926.
45. Haughn L., Hawley R.G., Morrison D.K., von Boehmer H., Hockenbery D.M. BCL-2 and BCL-XL restrict lineage choice during hematopoietic differentiation. J. Biol. Chem. 2003, 278:25158-25165.
46. Haydar T.F., Wang F., Schwartz M.L., Rakic P. Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J. Neurosci. 2000, 20:5764-5774.
47. Hebsgaard J.B., Nelander J., Sabelstrom H., Jonsson M.E., Stott S., Parmar M. Dopamine neuron precursors within the developing human mesencephalon show radial glial characteristics. Glia 2009, 57:1648-1658.
48. Hedlund E., Pruszak J., Lardaro T., Ludwig W., Vinuela A., Kim K.S., Isacson O. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 2008, 26:1526-1536.
49. Hwang D.Y. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems. J. Cell. Biochem. 2010, 109:292-301.
50. Janumyan Y., Cui Q., Yan L., Sansam C.G., Valentin M., Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J. Biol. Chem. 2008, 283:34108-34120.
51. Jensen J.B., Parmar M. Strengths and limitations of the neurosphere culture system. Mol. Neurobiol. 2006, 34:153-161.
52. Jones R.G., Bui T., White C., Madesh M., Krawczyk C.M., Lindsten T., Hawkins B.J., Kubek S., Frauwirth K.A., Wang Y.L., Conway S.J., Roderick H.L., et al. The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity 2007, 27:268-280.
53. Kele J., Simplicio N., Ferri A.L., Mira H., Guillemot F., Arenas E., Ang S.L. Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. Development 2006, 133:495-505.
54. Khan Z., Akhtar M., Asklund T., Juliusson B., Almqvist P.M., Ekström T.J. HDAC inhibition amplifies gap junction communication in neural progenitors: Potential for cell-mediated enzyme prodrug therapy. Exp. Cell Res. 2007, 313:2958-2967.
55. Kim H.J. Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamineneurons. Biochim. Biophys. Acta 2011, 1812:1-11.
56. Kim H.J., Sugimori M., Nakafuku M., Svendsen C.N. Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Exp. Neurol. 2007, 203:394-405.
57. Kim H.J., McMillan E., Han F., Svendsen C.N. Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. Stem Cells 2009, 27:390-398.
58. Koch P., Opitz T., Steinbeck J.A., Ladewig J., Brustle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl. Acad. Sci. USA 2009, 106:3225-3230.
59. Koch P., Kokaia Z., Lindvall O., Brustle O. Emerging concepts in neural stem cell research: Autologous repair and cell-based disease modeling. Lancet Neurol. 2009, 8:819-829.
60. Krabbe C., Courtois E., Jensen P., Jorgensen J.R., Zimmer J., Martinez-Serrano A., Meyer M. Enhanced dopaminergic differentiation of human neural stem cells by synergistic effect of Bcl-xL and reduced oxygen tension. J. Neurochem. 2009, 110:1908-1920.
61. Krajewska M., Mai J.K., Zapata J.M., Ashwell K.W., Schendel S.L., Reed J.C., Krajewski S. Dynamics of expression of apoptosis-regulatory proteins Bid, Bcl-2, Bcl-X, Bax and Bak during development of murine nervous system. Cell Death Differ. 2002, 9:145-157.
62. Krantic S., Mechawar N., Reix S., Quirion R. Apoptosis-inducing factor: A matter of neuron life and death. Prog. Neurobiol. 2007, 81:179-196.
63. Kretz A., Kugler S., Happold C., Bahr M., Isenmann S. Excess Bcl-XL increases the intrinsic growth potential of adult CNS neurons in vitro. Mol. Cell. Neurosci. 2004, 26:63-74.
64. Kuranaga E. Caspase signaling in animal development. Dev. Growth Differ. 2011, 53:137-148.
65. Kuranaga E., Miura M. Nonapoptotic functions of caspases: Caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell Biol. 2007, 17:135-144.
66. Lee H.S., Bae E.J., Yi S.H., Shim J.W., Jo A.Y., Kang J.S., Yoon E.H., Rhee Y.H., Park C.H., Koh H.C., Kim H.J., Choi H.S., et al. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 2010, 28:501-512.
67. Lenos M.G., Tsaniklidou S.M. Calcium oscillations, G1 phase duration and neurogenesis timing. Trends Cell Biol. 2010, 20:577. (author reply 578).
68. Lew M. Overview of Parkinson's disease. Pharmacotherapy 2007, 27:155S-160S.
69. Li C., Fox C.J., Master S.R., Bindokas V.P., Chodosh L.A., Thompson C.B. Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc. Natl. Acad. Sci. USA 2002, 99:9830-9835.
70. Li C., Wang X., Vais H., Thompson C.B., Foskett J.K., White C. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc. Natl. Acad. Sci. USA 2007, 104:12565-12570.
71. Li H., Chen Y., Jones A.F., Sanger R.H., Collis L.P., Flannery R., McNay E.C., Yu T., Schwarzenbacher R., Bossy B., Bossy-Wetzel E., Bennett M.V., et al. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 2008, 105:2169-2174.
72. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
73. Li J.Y., et al. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 2008, 31:146-153.
74. Lindsten T., Zong W.X., Thompson C.B. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005, 11:10-15.
75. Lindvall O., Björklund A. Cell therapy in Parkinson's disease. NeuroRx. 2004, 1:382-393.
76. Lindvall O., Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinsońs disease. Trends Pharmacol. Sci. 2009, 30:260-267.
77. Lindvall O., Kokaia Z. Stem cells in human neurodegenerative disorders- time for clinical translation?. J. Clin. Invest. 2010, 120:29-40.
78. Lindvall O., Kokaia Z., Martínez-Serrano A. Stem cell therapy for human neurodegenerative disorders-How to make it work. Nat. Med. 2004, 10(Suppl.):S42-S50.
79. Lipskaia L., Hulot J.S., Lompre A.M. Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Arch. 2009, 457:673-685.
80. Liste I., Garcia-Garcia E., Martinez-Serrano A. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo. J. Neurosci. 2004, 24:10786-10795.
81. Liste I., Garcia-Garcia E., Bueno C., Martinez-Serrano A. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ. 2007, 14:1880-1892.
82. Lister R., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
83. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 2002, 277:38884-38894.
84. Maciaczyk J., Singec I., Maciaczyk D., Nikkhah G. Combined use of BDNF, ascorbic acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. Exp. Neurol. 2008, 213:354-362.
85. Mahler J., Filippi A., Driever W. DeltaA/DeltaD regulate multiple and temporally distinct phases of notch signaling during dopaminergic neurogenesis in zebrafish. J. Neurosci. 2010, 30:16621-16635.
86. 2+ and cAMP signaling in human embryonic stem cell-derived dopamine neurons. Stem Cells Dev. 2010, 19(9):1355-1364.
87. Martinez-Serrano A., Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci. 1997, 20:530-538.
88. Martínez-Serrano A., Liste I. Recent progress and challenges for the use of stem cell derivatives in neuron replacement therapy for Parkinson's disease. Future neurol. 2010, 5:161-165.
89. Meissner W.G., Frasier M., Gasser T., Coetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Schapira A., Voon V., Weiner D.M., Tison F., et al. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
90. Meyer A.K., Maisel M., Hermann A., Stirl K., Storch A. Restorative approaches in Parkinson's disease: Which cell type wins the race?. J. Neurol. Sci. 2010, 289:93-103.
91. Miljan E.A., Hines S.J., Pande P., Corteling R.L., Hicks C., Zbarsky V., Umachndran M., Sowinski P., Richardon S., Tang E., Wieruszew M., Patel S., et al. Implantation of c-mycERTAM immortalized human mesencephalic-derived clonal cell lines ameliorates behavior dysfunction in a rat model of Parkinson's disease. Stem Cells Dev. 2009, 18:307-319.
92. Motoyama N., Wang F., Roth K.A., Sawa H., Nakayama K., Negishi I., Senju S., Zhang Q., Fujii S., et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995, 267:1506-1510.
93. Nair V.D., McNaught K.S., Gonzalez-Maeso J., Sealfon S.C., Olanow C.W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 2006, 281:39550-39560.
94. Nakatani T., Kumai M., Mizuhara E., Minaki Y., Ono Y. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control floor plate cell differentiation in the developing mesencephalon. Dev. Biol. 2010, 339:101-113.
95. Nelander J., Hebsgaard J.B., Parmar M. Organization of the human embryonic ventral mesencephalon. Gene Expr. Patterns 2009, 9:555-561.
96. Nguyen L., Besson A., Roberts J.M., Guillemot F. Coupling cell cycle exit, neuronal differentiation and migration in cortical neurogenesis. Cell Cycle 2006, 5:2314-2318.
97. Nguyen H.N., et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8:267-280.
98. Obeso J.A., Rodríguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H.V., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:563-661.
99. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22:123-144.
100. Ono Y., Nakatani T., Sakamoto Y., Mizuhara E., Minaki Y., Kumai M., Hamaguchi A., Nishimura M., Inoue Y., Hayashi H., Takahashi J., Imai T. Differences in neurogenic potential in floor plate cells along an anteroposterior location: Midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007, 134:3213-3225.
101. Ono Y., Nakatani T., Minaki Y., Kumai M. The basic helix-loop-helix transcription factor Nato3 controls neurogenic activity in mesencephalic floor plate cells. Development 2010, 137:1897-1906.
102. Orme R., Fricker-Gates R.A., Gates M.A. Ontogeny of substantia nigra dopamine neurons. J. Neural Transm. Suppl. 2009, 73:3-18.
103. Ostenfeld T., Joly E., Tai Y.T., Peters A., Caldwell M., Jauniaux E., Svendsen C.N. Regional specification of rodent and human neurospheres. Brain Res. Dev. Brain Res. 2002, 134:43-55.
104. Parsadanian A.S., Cheng Y., Keller-Peck C.R., Holtzman D.M., Snider W.D. Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. J. Neurosci. 1998, 18:1009-1019.
105. Paul G., Christophersen N.S., Raymon H., Kiaer C., Smith R., Brundin P. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line-studies in vitro and after intracerebral grafting in vivo. Mol. Cell. Neurosci. 2007, 34:390-399.
106. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., Harrison N.L., Studer L. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 2004, 101:12543-12548.
107. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell Rehncrona S., Widner H., Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
108. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., Quinn N.P., Brooks D.J., Lindvall O. Factors affecting the clinical outcome after neural transplantaion in Parkinson's disease. Brain 2005, 128:2977-2986.
109. Pinton P., Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ. 2006, 13:1409-1418.
110. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Bjorklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's disease patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
111. Prakash N., Wurst W. Genetic netwrls controlling the development of midbrain dopaminergic neurons. J. Physiol. 2006, 575:403-410.
112. Puelles E. Genetic control of basal midbrain development. J. Neurosci. Res. 2007, 85:3530-3534.
113. Puelles E., Annino A., Tuorto F., Usiello A., Acampora D., Czerny T., Brodski C., Ang S.L., Wurst W., Simeone A. Otx2 regulates the extent, identity and fate of neuronal progenitor domains in the ventral midbrain. Development 2004, 131:2037-2048.
114. Resende R.R., Gomes K.N., Adhikari A., Britto L.R., Ulrich H. Mechanism of acetylcholine-induced calcium signaling during neuronal differentiation of P19 embryonal carcinoma cells in vitro. Cell Calcium 2008, 43:107-121.
115. Riaz S.S., Theofilopoulos S., Jauniaux E., Stern G.M., Bradford H.F. The differentiation potential of human foetal neuronal progenitor cells in vitro. Brain Res. Dev. Brain Res. 2004, 153:39-51.
116. Roy N.S., et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 2006, 12:1259-1268.
117. Roybon L., Hjalt T., Christophersen N.S., Li J.Y., Brundin P. Effects on differentiation of embryonic ventral midbrain progenitors by Lmx1a, Msx1, Ngn2, and Pitx3. J. Neurosci. 2008, 28:3644-3656.
118. Ryu J.K., Choi H.B., Hatori K., Heisel R.L., Pelech S.L., McLarnon J.G., Kim S.U. Adenosine triphosphate induces proliferation of human neural stem cells: Role of calcium and p70 ribosomal protein S6 kinase. J. Neurosci. Res. 2003, 72:352-362.
119. Sacchetti P., et al. Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell 2009, 5(4):409-419.
120. Salomoni P., Calegari F. Cell cycle control of mammalian neural stem cells: Putting a speed limit on G1. Trends Cell Biol. 2010, 20:233-243.
121. Savitt J.M., Jang S.S., Mu W., Dawson V.L., Dawson T.M. Bcl-x is required for proper development of the mouse substantia nigra. J. Neurosci. 2005, 25:6721-6728.
122. Schulz R., Vogel T., Dressel R., Krieglstein K. TGF-beta superfamily members, ActivinA and TGF-beta1, induce apoptosis in oligodendrocytes by different pathways. Cell Tissue Res. 2008, 334:327-338.
123. Shim J.W., Koh H.C., Chang M.Y., Roh E., Choi C.Y., Oh Y.J., Son H., Lee Y.S., Studer L., Lee S.H. Enhanced in vitro midbrain dopamine neuron differentiation, dopaminergic function, neurite outgrowth, and 1-methyl-4-phenylpyridium resistance in mouse embryonic stem cells overexpressing Bcl-XL. J. Neurosci. 2004, 24:843-852.
124. Smidt M.P., Burbach J.P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 2007, 8:21-32.
125. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
126. Storch A., Paul G., Csete M., Boehm B.O., Carvey P.M., Kupsch A., Schwarz J. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp. Neurol. 2001, 170:317-325.
127. Studer L., Tabar V., McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1998, 1:290-295.
128. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
129. Tang M., Villaescusa J.C., Luo S.X., Guitarte C., Lei S., Miyamoto Y., Taketo M.M., Arenas E., Huang E.J. Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J. Neurosci. 2010, 30:9280-9291.
130. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
131. Tønessen J., Seiz E.G., Ramos M., Lindvall O., Martínez-Serrano A., Kokaia M. Functional properties of the human ventral mesecephalic neural stem cells line hVM1. Exp. Neurol. 2010, 223:653-656.
132. Tzschentke T.M., Schmidt W.J. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit. Rev. Neurobiol. 2000, 14:131-142.
133. Villa A., Liste I., Courtois E.T., Seiz E.G., Ramos M., Meyer M., Juliusson B., Kusk P., Martinez-Serrano A. Generation and properties of a new human ventral mesencephalic neural stem cell line. Exp. Cell Res. 2009, 315:1860-1874.
134. Weissman T.A., Riquelme P.A., Ivic L., Flint A.C., Kriegstein A.R. Calcium waves propagate through radial glial cells and modulate proliferation in the developing neocortex. Neuron 2004, 43:647-661.
135. White C., Li C., Yang J., Petrenko N.B., Madesh M., Thompson C.B., Foskett J.K. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat. Cell Biol. 2005, 7:1021-1028.
136. Winkler C., Kirirk D., Björklund A. Cell transplantation in Parkinson's disease: How can we make it work?. Trends Neurosci. 2005, 28:86-92.
137. Xiong N., Zhang Z., Huang J., Chen C., Jia M., Xiong J., Liu X., Wang F., Cao X., Liang Z., Sun S., Lin Z., et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 2011, 18:394-402.
138. Yan J., Studer L., McKay R.D.G. Ascorbic acid increases de yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors. J. Neurochem. 2001, 76:307-311.
139. Yu J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
140. Zaidi A.U., D'Sa-Eipper C., Brenner J., Kuida K., Zheng T.S., Flavell R.A., Rakic P., Roth K.A. Bcl-X(L)-caspase-9 interactions in the developing nervous system: Evidence for multiple death pathways. J. Neurosci. 2001, 21:169-175.